Disease relevance of Loteprednol etabonate

• A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis [1].
• OBJECTIVES: The objective of this study was to evaluate the effects of 0.2% loteprednol etabonate in reducing the signs and symptoms of seasonal allergic conjunctivitis [1].
• A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance [2].
• In conclusion, all steroid treatments reduced uveitis to some degree but LE was consistently effective [3].

High impact information on Loteprednol etabonate

• No patients in either treatment group (0 for loteprednol etabonate and 0 for vehicle) had an elevation of intraocular pressure of 10 mm Hg or greater during the 6 weeks of treatment [1].
• BACKGROUND: Loteprednol etabonate is a site-active corticosteroid with efficacy and safety in treating ocular inflammation at the 0.5% concentration [1].
• Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol [4].
• Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study [5].
• BACKGROUND: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topical antiallergic agents indicated for treatment of the signs and symptoms of allergic conjunctivitis and seasonal allergic conjunctivitis (SAC), respectively [6].

Biological context of Loteprednol etabonate

• Pharmacokinetics, metabolism and excretion of loteprednol etabonate (LE) were investigated in rats [7].
• Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs" [8].
• Prednisolone, in brand or generic form, was used by 37 to 90% for routine management in various clinical scenarios and 81 to 91% for various manifestations of graft rejection at all time points; however, after 6 months, 12 to 26% used loteprednol etabonate for routine management [9].
• Loteprednol etabonate has been developed on the basis of the retrometabolic drug design [10].
• Loteprednol etabonate belongs to the so-called class of soft steroids because it is metabolized by a one-step reaction (hydrolysis) without using the cytochrome P450 monooxygenase system [11].

Anatomical context of Loteprednol etabonate

• Confocal microscopy indicated that only treatment with LE reverted the abnormal endothelial-cell shape to normal [3].

Associations of Loteprednol etabonate with other chemical compounds

• PURPOSE: Loteprednol etabonate is a novel site-active corticosteroid synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite [12].
• Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea [13].
• Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation [14].
• Rimexolone and loteprednol etabonate, two new corticosteroids, may offer good antiinflammatory efficacy with greatly reduced risk for elevation of intraocular pressure [15].

Gene context of Loteprednol etabonate

• Only LE and PRED F treatments significantly internalized GC receptor after 72 hours of treatment [3].

Analytical, diagnostic and therapeutic context of Loteprednol etabonate

• As a safe anti-inflammatory corticosteroid, the utility of loteprednol etabonate (LE) for the treatment of gastrointestinal inflammation, via oral and rectal administration, was investigated in rats [16].
• The treatment failure rate and the time course of failures were lower in the loteprednol etabonate group; the differences were clinically meaningful and statistically significant (P < .001) [17].
• An HPLC method to evaluate purity of a steroidal drug, loteprednol etabonate [18].
• Lotemax (0.5% LE) has been demonstrated as effective in reducing the signs and symptoms of giant papillary conjunctivitis (GPC), acute anterior uveitis and inflammation following cataract extraction with intraocular lens (IOL) implantation [19].

References